Fresenius SE & Co. KGaA’s (FRE) “Buy” Rating Reiterated at Citigroup

Fresenius SE & Co. KGaA (FRA:FRE)‘s stock had its “buy” rating reissued by analysts at Citigroup in a report released on Friday.

A number of other equities research analysts have also recently issued reports on FRE. Goldman Sachs Group set a €74.50 ($88.69) price objective on shares of Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Friday. UBS set a €74.00 ($88.10) price target on shares of Fresenius SE & Co. KGaA and gave the company a “neutral” rating in a report on Friday, August 18th. Deutsche Bank set a €85.00 ($101.19) price target on shares of Fresenius SE & Co. KGaA and gave the company a “buy” rating in a report on Tuesday, August 8th. Independent Research set a €80.00 ($95.24) price target on shares of Fresenius SE & Co. KGaA and gave the company a “buy” rating in a report on Thursday, November 23rd. Finally, Morgan Stanley set a €83.00 ($98.81) target price on shares of Fresenius SE & Co. KGaA and gave the company a “buy” rating in a research note on Wednesday, October 4th. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of €79.54 ($94.69).

Shares of Fresenius SE & Co. KGaA (FRA:FRE) opened at €60.56 ($72.10) on Friday. Fresenius SE & Co. KGaA has a fifty-two week low of €60.56 ($72.10) and a fifty-two week high of €80.00 ($95.24).

WARNING: “Fresenius SE & Co. KGaA’s (FRE) “Buy” Rating Reiterated at Citigroup” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://transcriptdaily.com/2017/12/01/fresenius-se-co-kgaas-fre-buy-rating-reiterated-at-citigroup.html.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co. KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply